FP6Reintegration grant2004–2005

CELL TRANSPLANTATION · Use of embryonic stem cells and organotypic spinal cord slice preparations to establish cell-based therapies for spinal cord injury

FP6 — Marie Curie Actions (Human Resources and Mobility)

Duration
2004-07-15 → 2005-07-14
EU contribution
€39,691
Participants
1
Scheme
ERG

Lines connect the coordinator with its partners.

Results in brief

Final Activity Report Summary - CELL TRANSPLANTATION (Use of embryonic stem cells and organotypic spinal cord slice preparations to establish cell-based therapies for spinal cord injury)

Cell transplantation has become a promising treatment for neurodegenerative diseases and trauma in the Central nervous system (CNS). The overall objective of this project was to investigate and optimise possible therapeutic strategies for Spinal cord injury (SCI) via combination of cell-based therapies with concurrent or sequential application of neuroprotective and proregenerative factors. Animal models for SCI were valuable for the advance in understanding cellular mechanisms that promoted neuroprotection and regeneration. However, due to the complexity of in vivo systems in providing easy result interpretations and the increased cost-effectiveness, in vitro systems might be advantageous for initial assays. For this purpose, we generated two neurotrauma models of SCI by using organotypic cultures of spinal cord, which maintained the basic cord cytoarchitecture and dorsal-ventral orientation. Considering that excitatory aminoacids were proposed as a potential cause for secondary injury after SCI, one injury model was based on the induction of neuronal death by the application of 50 µM glutamate. The second model of in vitro neurotrauma was based on the application of a mechanical insult by rolling a cylinder on the slice. Immunohistochemical analysis confirmed that these models caused 96.1 % and 95.8 % of neuronal death, respectively. These models were used to analyse the neuroprotective effect of FK506, a commonly used immunosuppressant drug. We found that the general cytoarchitecture of the spinal cord explants was better preserved in the presence of FK506 after excytotoxic induction, however only mild neuronal survival was obtained, equal to 8.9 %. Considering that the number of neurons recovered was still modest, we attempted to implement a combined strategy via the use of cell grafting to restitute lost cells. Thus, we employed neural-derived embryonic stem cells for this purpose. Before the grafting experiments we tried to improve a classical protocol for neural Embryonic stem (ES) cell differentiation in order to enrich the production of cholinergic neurons. Cholinergic neurons could potentially substitute motoneurons that were lost in the injured spinal cord. We succeeded in promoting the observation that all neurons obtained by ES cells expressed a cholinergic phenotype, namely Choline acetyl transferase (ChAT) plus, by using the morphogen sonic hedgehog and retinoic acid. Then, pre-differentiated ES cells were placed on control and injured spinal cord slices to assess for their differentiation after grafting. These cells were also grafted on the neurotrauma in vitro models in combination with FK506. The analyses of these assays were in progress by the time of the project completion. We also assessed the neuroprotective potential of different drugs. The results obtained from these studies were anticipated to provide valuable information about the action of different drugs on neuronal survival and would allow us to establish the optimal therapeutic combination to subsequently explore in vivo animal models for SCI.

Data: CORDIS, © European Union

Project objective

The disruption of spinal cord motor and sensory pathways following traumatic injury has devastating consequences for damaged patients. Regenerative strategies include the use of cell-based therapies to bridge the lesion. The main objective of this project is to investigate and optimise therapeutic strategies for spinal cord injury (SCI) by combining cell-based therapies with concurrent or sequential application of neuro-protective and/or regenerative pro-factors. We intend to obtain neural-derived embryonic s tem cells to be used for transplantation as prime experiments reported shed hopeful results. However, several questions remain unsolved critical to plan optimised therapies. One of these issues is the mechanism involved regenerative event after cell grafting. By using genetically engineered embryonic stem (ES) cells, we should be able to determine whether regeneration is specifically promoted by cell integration itself into the repaired tissue or by the factors released by them.An optimal therapeutic strategy for SCI using ES cells will be selected using an in vitro model for neurotrauma based on organotypic spinal cord slice preparations. The establishment of this model is another objective of the project and should facilitate the efficient screening of a broad spectrum of factors in combination with cell graft. It may reduce notably the number of animals destined for this purpose. The most advantageous strategy, derived from this screening will be analysed in vivo on murine models for SCI and functional recovery will be evaluated by a complete battery of electrophysiological and behaviour tests. In summary, the accomplishment of those objectives should shed light into essential neural regenerative processes, may provide innovative systems for high-throughput screenings and should determine optimal therapeutic strategies to repair injured spinal cords.

Original text from CORDIS.

Participants

  • UNIVERSITAT AUTONOMA DE BARCELONA · BELLATERRA (CERDANYOLA DEL VALLES)CoordinatorSpain

Links

Data: CORDIS, © European Union